HOME                OUR TEAM               NEWS                 PIPELINE                CONTACT US

PIPELINE

Inhaled Cyclosporine

Inhaled Anti-Inflammatory Agent

Inhaled Immunomodulator

Inhaled Hydroxychloroquine (HCQ)

 

  
     
 
   

Inhaled Cyclosporine

Inhaled cyclosporine is a treatment intended to prevent rejection and prolong survival in lung transplant patients.

  
     
       
   

Clinical Trials Now Enrolling

For information on APT Pharmaceuticals' clinical trials of inhaled cyclosporine in lung transplant recipients, please follow links below:

Cyclosporine Inhalation Solution (CIS)
in Lung Transplant Recipients

Study of Cyclosporine Inhalation Solution (CIS)
in Improving Bronchiolitis Obliterans Syndrome-Free
Survival Following Lung Transplantation (CIS001)

  
       
     
       
   

A long-term study of inhalable cyclosporine was conducted in 56 lung transplant recipients at the University of Pittsburgh Medical Center, a nationally recognized transplant center, and published in the New England Journal of Medicine in 2006 (reference). Patients that received inhalable cyclosporine in addition to their standard immunosuppressive treatment showed a 78% reduction in mortality compared to those in the control group, who received conventional immunosuppressive treatments.

New England Journal of Medicine 354:2 pp141-150, 2006
"A Randomized Trial of Inhalable Cyclosporine in Lung-Transplant Recipients"
Click above to read the January 12, 2006 New England Journal of Medicine article about inhalable cyclosporine.

  
       
    "We think that inhalable cyclosporine will significantly extend the lives of lung transplant recipients. We are very excited that APT is dedicating the majority of its focus to develop a well-tolerated and user-friendly form of this important and effective immunosuppressant"  
       
   
 
Dr. Joseph Pilewski
Medical Director of the Lung Transplant Program
at University of Pittsburgh Medical Center.
 
       
       
       
       
©2007 APT PHARMACEUTICALS, INC.